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Abstract
Augmentation of immunogenicity can be achieved by particulate delivery of an antigen and by its 
co-administration with an adjuvant. However, many adjuvants initiate strong systemic 
inflammatory reactions in vivo, leading to potential adverse events and safety concerns. We have 
developed a synthetic vaccine particle (SVP) technology that enables co-encapsulation of antigen 
with potent adjuvants. We demonstrate that co-delivery of an antigen with a TLR7/8 or TLR9 
agonist in synthetic polymer nanoparticles results in a strong augmentation of humoral and cellular 
immune responses with minimal systemic production of inflammatory cytokines. In contrast, 
antigen encapsulated into nanoparticles and admixed with free TLR7/8 agonist leads to lower 
immunogenicity and rapid induction of high levels of inflammatory cytokines in the serum (e.g., 
TNF-α and IL-6 levels are 50- to 200-fold higher upon injection of free resiquimod (R848) than of 
nanoparticle-encapsulated R848). Conversely, local immune stimulation as evidenced by cellular 
infiltration of draining lymph nodes and by intranodal cytokine production was more pronounced 
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and persisted longer when SVP-encapsulated TLR agonists were used. The strong local immune 
activation achieved using a modular self-assembling nanoparticle platform markedly enhanced 
immunogenicity and was equally effective whether antigen and adjuvant were co-encapsulated in a 
single nanoparticle formulation or co-delivered in two separate nanoparticles. Moreover, particle 
encapsulation enabled the utilization of CpG oligonucleotides with the natural phosphodiester 
backbone, which are otherwise rapidly hydrolyzed by nucleases in vivo. The use of SVP may 
enable clinical use of potent TLR agonists as vaccine adjuvants for indications where cellular 
immunity or robust humoral responses are required.
Keywords
Synthetic nanoparticle vaccine; TLR agonist; Adjuvant; CpG; R848; Resiquimod
1. Introduction
Vaccine adjuvants augment the immune response by promoting more effective antigen 
processing, presentation, and/or delivery [1]. Aluminum salts (alum) were first introduced as 
vaccine adjuvants over 80 years ago when little was known about the cellular or molecular 
mechanisms of the immune response [2], yet alum remains the most widely used adjuvant 
today due to its demonstrated safety profile and effectiveness when combined with many 
clinically important antigens [3,4]. However, alum is not sufficiently potent to attain 
protective responses to poorly immunogenic entities [5–9]. Additionally, alum preferentially 
promotes Th2 type responses [2–4,10], which may exacerbate adverse inflammatory 
reactions to some respiratory pathogens, such as the respiratory syncytial virus (RSV) [11], 
and does not efficiently augment cytotoxic T cell responses, which are necessary to provide 
protective immunity against many viral antigens or therapeutic immunity against cancer-
related antigens [12]. One of the main challenges of current vaccine development is to 
advance the clinical application of newly developed and potent adjuvants without 
compromising safety [12,13].
Novel adjuvant candidates have emerged from the discovery of pattern recognition receptors 
(PRR) that recognize pathogen-associated molecular patterns (PAMP) and damage-
associated molecular patterns (DAMP) [14–17]. Research on PRRs has provided insight into 
how the innate system activates and modulates the adaptive immune system [16]. Microbial 
PAMPs, such as lipopolysaccharides, single-stranded RNA, and bacterial DNA motifs, bind 
to a family of PRRs called Toll-like receptors (TLR) on innate immune cells and stimulate 
antigen processing and presentation [16–18]. TLRs are widely expressed on dendritic cells 
(DC) and other professional APCs such as macrophages and B cells. While some TLRs are 
expressed on the cell surface and act as sensors for extracellular PAMPs (e.g., 
lipopolysaccharides), a subset of TLR molecules (TLR3, 7, 8 and 9) are expressed on 
endosomal membranes and bind nucleic acid-derived molecules, such as single-stranded 
RNA of viral origin for TLR7 and 8 [19–24] and bacterial unmethylated DNA 
oligonucleotides (ODNs) containing CpG motifs (CpG ODNs) for TLR9 [14,25–28]. TLR 
ligands of natural and synthetic origin are potent inducers of innate immune responses and 
have been shown to effectively stimulate the transition from an innate immune response to 
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an adaptive immune response. As such, TLR agonists have been evaluated as potential 
adjuvants in a variety of applications [4].
To date, only one PRR ligand, 3-O-desacyl-4′-monophosphoryl lipid A (MPL), a TLR4 
agonist, has been included as an adjuvant in a FDA- or EMA-licensed vaccine. MPL 
adsorbed onto alum is utilized in the HPV vaccine Cervarix, licensed in the U.S. and Europe 
[29], and the hepatitis B vaccine Fendrix, licensed in Europe [30]. Imiquimod, a topically 
administered TLR7 agonist, has been approved for treatment of genital warts, actinic 
keratosis, and basal cell carcinoma [31]. Other TLR agonists, such as poly(I:C) (TLR3), 
imidazoquinolines other than imiquimod (TLR7, 8, or 7/8), and CpG ODNs (TLR9), have 
failed thus far to enter clinical practice as parenteral adjuvants despite a multitude of 
promising data obtained in preclinical and clinical studies [32–36]. One of the main reasons 
for this failure is the delicate balance between the induction of augmented immunogenicity 
by TLR agonists and safety concerns, which are often related to the generation of systemic 
inflammatory responses [19,37–39].
Several groups have utilized micro- and nanocarriers, such as virus-like particles, liposomes, 
and PLGA particles, to encapsulate adjuvants [40–42]. Encapsulation of adjuvants reduces 
systemic exposure of adjuvant and enhances uptake by APCs. Nano-size viruses and 
particles distribute rapidly to the local draining lymph node where they are taken up by 
subcapsular macrophages and dendritic cells [41,43,44]. Antigens can also be delivered in 
particles to target efficient uptake by APCs [36,41,45,46]. Recent studies show that co-
encapsulation of both antigen and adjuvant in nanoparticulate carriers have synergistic 
effects in augmenting immunity by targeting both antigen and adjuvant to the endosomal 
compartment of APCs [36,42,46].
In this study, we evaluated the immune responses induced by synthetic vaccine particles 
(SVP) carrying covalently bound or entrapped TLR agonist co-delivered with encapsulated 
antigen (either in the same or in separate nanoparticle preparations). We hypothesized that 
such an approach may provide a two-pronged benefit by enabling a focused delivery of 
antigen and adjuvant and hence enhancing immunogenicity while preventing systemic 
exposure of the TLR agonist, which can result in excessive systemic cytokine release. 
Indeed, encapsulation of TLR agonist changed the dynamics of cytokine induction in vitro 
and in vivo. Systemic cytokine production observed with free resiquimod (R848) was 
suppressed by its encapsulation within nanoparticles. At the same time, SVP-encapsulated 
TLR agonists, but not free TLR agonists, promoted sustained cytokine induction in the local 
draining lymph node as well as a robust infiltration by APCs and, later, by antigen-
responsive cells. SVP-encapsulated TLR7/8 and TLR9 ligands augmented humoral and 
cellular immune responses to both soluble and nanoparticle-delivered protein compared to 
that observed with free adjuvants. Furthermore, this augmentation did not require co-
encapsulation of antigen and TLR agonist in the same SVP. Collectively, these data indicate 
that SVPs may enable the use of potent TLR agonists as novel adjuvants by targeting their 
activity to the draining lymph node and minimizing systemic exposure, thereby reducing 
adjuvant-related side effects.
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2. Materials and methods
2.1. Mice
Six- to eight-week-old female C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA, USA) or Taconic (Germantown, NY, USA). All animal 
protocols were reviewed and approved by IACUC in accordance with federal, state and city 
of Cambridge (MA, USA) regulations and guidelines.
2.2. Cells and reagents
Fresh murine splenocytes were cultivated in RPMI with 10% FBS and were assayed in 96-
well plates at 20,000–50,000 cells/well. Cell lines J774 (murine macrophages), EL4 (H-2b 
murine thymoma), and E.G7-OVA (EL4 cells transfected with full the length gene encoding 
chicken OVA) were purchased from the ATCC (American Type Culture Collection, 
Rockville, MD, USA) and grown per manufacturer’s recommendations. R848 was 
purchased from Enzo Life Sciences (Farmingdale, NY, USA) or Princeton Global Synthesis 
(Bristol, PA, USA). Phosphorothioate (PS) or phosphodiester (PO) forms of CpG-1826 (5′-
TCCATGACGTTCCTGACGTT-3′) were purchased either from Enzo Life Sciences or from 
Oligo Factory (Holliston, MA, USA). OVA was purchased from Worthington Biochemical 
Corporation (Lakewood, NJ, USA). Recombinant prostatic acid phosphatase (PAP) was 
expressed in Escherichia coli and purified by Virogen (Watertown, MA, USA). Aluminum 
hydroxide gel (alum) was purchased from Sigma–Aldrich (St. Louis, MO, USA).
The poly(lactide) or poly(lactide-co-glycolide) polymers (PLA or PLGA) were purchased 
from Lakeshore Biomaterials (Birmingham, AL, USA) unless otherwise specified. 
Poly(lactide)-bl-poly(ethylene glycol) monomethyl ether diblock copolymer (PLA-PEG-
OMe) was prepared according to the literature [47,48]. Dichloromethane (CH2Cl2), 
acetonitrile, HPLC grade water, triethylamine (TEA), and trifluoroacetic acid (TFA) were 
purchased from VWR International (Radnor, PA, USA). Dimethylsulfoxide (DMSO) was 
purchased from Sigma–Aldrich. Fluorescamine was purchased from Tokyo Chemical 
Industry America (Waltham, MA, USA). Cellgro PBS 1X (PBS) was purchased from 
Mediatech, Inc. (Manassas, VA, USA). PLGA-R848 polymer was prepared by Princeton 
Global Synthesis. Polyvinyl alcohol was purchased from EMD Millipore (Billerica, MA, 
USA).
2.3. SVP preparation and analysis
All of the SVP were prepared using a double emulsion water/oil/water system [49]. Briefly, 
the polymers were prepared at 10% wt/vol in CH2Cl2, and OVA was prepared at 50 mg/mL 
in PBS. In formulations without OVA, we substituted the OVA aqueous phase with PBS. 
Emulsification via sonication was performed using a Branson Digital Sonifier model 250 
equipped with a model 102 C converter and a 1/8” tapered microtip from Branson 
Ultrasonics (Danbury, CT, USA). Centrifugation was carried out using a Beckman Coulter 
J-30I centrifuge with a JA-30.50 rotor (Beckman Coulter, Brea, CA, USA). The primary 
emulsion was carried out in a thick walled glass pressure tube with an aqueous to organic 
phase ratio of 1:5. Following a brief sonication step, Emprove PVA 4–88 aqueous solution 
was added to the polymer organic solution (at a volume ratio of 3:1 PVA to organic phase), 
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vortex mixed, and emulsified by sonication. The resultant double emulsion was then 
transferred into a beaker under stirring containing 70 mM phosphate buffer pH 8.0 at a 
volume ratio of 1 part double emulsion to 7.5 parts buffer. The organic solvent (CH2Cl2) was 
allowed to evaporate for 2 h under stirring, and the nanoparticles were recovered via 
centrifugation at 75,600 rcf with two wash steps. PBS was used for the wash solutions and 
the final resuspension media. The washed SVP suspension was stored at −20 °C.
Determination of OVA loading was performed using the fluorescamine test from Udenfriend 
et al. [50]. R848 and CpG loading were each determined by SVP hydrolysis followed by 
reversed-phase HPLC analysis. Briefly, nanoparticle solutions were centrifuged, and the 
pellets were subjected to base hydrolysis to release the adjuvant. R848 hydrolysis was 
carried out at room temperature using concentrated ammonium hydroxide. Results were 
quantified from the absorption of R848 at 254 nm using mobile phases comprised of water/
acetonitrile/TFA. For CpG analysis, NaOH was used at elevated temperature, with results 
quantified from the absorption of CpG at 260 nm. The HPLC mobile phases for CpG 
analysis used acetonitrile/water/TEA.
The SVP concentration was determined gravimetrically. Briefly, aliquots of SVP were 
centrifuged at 108,800 rcf to pellet out the nanoparticles. The supernatant was discarded, 
and the pellet was dried (72 h, 37 °C, atmospheric pressure). SVP concentrations were 
calculated by comparing the weight of the microtube at each of the following steps: empty, 
with the nanoparticle solution, with the supernatant discarded, and then after the incubator 
drying step.
2.4. Vaccination
Groups of 3–10 mice were injected s.c. in the hind limb with PBS vehicle containing SVP-
formulated or free antigens and adjuvants either in both limbs (30 μl volume per a single 
injection site, 60 μl total) or in a single limb (60 μl total volume). The standard SVP 
injection dose was 100 μg per animal (unless specified otherwise). A single time-point 
injection was used in cytokine production and T cell induction experiments, and prime-boost 
regimens (2–3 immunizations with 14 or 28-day intervals; detailed in figure legends) were 
used in experiments assessing antibody generation. Intranasal inoculation in both nares (60 
μl total volume) was done at a single time-point under light anesthesia.
2.5. Determination of antibody titers by ELISA
96-Well Costar plates (Corning Inc., Corning, NY, USA) were coated with 100 μl per well of 
OVA protein (5 μg/mL) or prostatic acid phosphatase (PAP) protein (1 μg/mL; Virogen) and 
incubated overnight at 4 °C. Plates were washed three times with 0.05% Tween-20 in PBS, 
300 μl diluent (1% casein in PBS; Thermo Fisher, Waltham, MA, USA) was added to each 
well to block non-specific binding, and plates were incubated for at least 2 h at room 
temperature (RT). Plates were washed as described above, and serum samples were serially 
diluted 3-fold down the plate and incubated for 2 h at RT. Two columns of standards were 
included on each plate (anti-OVA monoclonal antibody, Abcam, Cambridge, MA, USA) 
starting at 0.25 μg/mL and diluted 3-fold down the plate. Naive mouse serum was used as a 
negative control. Plates were washed and detection antibody (either biotinylated goat anti-
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mouse Ig (BD Biosciences, San Jose, CA, USA) or horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Abcam)) was added to each well. For antibody isotyping, 
goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL, USA) and anti-mouse IgG2c 
(Bethyl Laboratories, Montgomery, TX, USA) (both HRP-conjugated) were used. Plates 
were incubated in the dark for 1 h at RT and washed (three times, with at least a 30-s soak 
between each wash). For plates with biotinylated antibodies, plates were incubated for 30 
min in the dark at RT with streptavidin–HRP (BD Biosciences) and washed (three times, 
with at least a 30-s soak between each wash). TMB substrate (BD Biosciences, San Jose, 
CA, USA) was added, and plates were incubated for 10 or 15 min in the dark. The reaction 
was stopped by adding stop solution (2N H2SO4) to each well, and the OD was measured at 
450 nm with subtraction of the 570 nm reading using a Versamax plate reader (Molecular 
Devices, Sunnyvale, CA, USA). Data analysis was performed using SoftMax Pro v5.4 
(Molecular Devices). A four-parameter logistic curve-fit graph was prepared with the serum 
dilution on the x-axis (log scale) and the OD value on the y-axis (linear scale), and the half 
maximum value (EC50) for each sample was determined to calculate antibody titer.
2.6. Lymph node preparation for lymphocyte cultivation
Four days post s.c. injection with SVP or free antigen (alone or with TLR agonist), mice 
were sacrificed, draining popliteal lymph nodes aseptically removed and digested for 30 min 
at 37 °C in 400 U/mL collagenase type 4 (Worthington, Lakewood, NJ, USA). Single cell 
suspensions were prepared by forcing digested lymph nodes through a 70-μm nylon filter 
membrane, then washed in PBS containing 2% FBS and counted using a Countess® cell 
counter (Life Technologies, Carlsbad, CA, USA). Lymph node derived lymphocytes were 
then seeded at 5 × 106 cells/mL in 96-well plate (round-bottom) and cultured for an 
additional 4 days in RPMI-1640 supplemented with 10% (v/v) heat inactivated FBS, 10 
U/mL recombinant human IL-2, 50 μM 2-ME, and antibiotics (penicillin-G and 
streptomycin sulphate, both at 100 IU/mL).
2.7. In vitro cytotoxicity
OVA specific cytolytic activity in vitro was determined via lactate dehydrogenase (LDH) 
release CytoTox96 Assay (Promega, Madison, WI, USA) according to manufacturer’s 
recommendations. Briefly, effector lymphocytes were cultured in limiting dilution either 
alone or with appropriate target cells, EL4 or E.G7-OVA at 37 °C for 18 h. CTL activity was 
assessed by measuring relative LDH with maximum and spontaneous release values 
measured against LDH within supernatants of effector target combinations. Specific lysis 
was calculated as follows: percent specific lysis (%) = 100 × [(experimental – T cell sponta 
neous)/(target max – target spontaneous)].
2.8. In vivo cytotoxicity
OVA-specific cytolytic activity in vivo was determined as described [51] at 6 days after a 
single immunization. Briefly, splenocytes from syngeneic naïve mice were labeled with 
either 0.5 μM, or 5 μM CFSE, resulting in CFSElow and CFSEhigh cell populations, 
correspondingly. CFSEhigh cells were incubated with 1 μg/mL of SIINFEKL peptide at 
37 °C for 1 h, while CFSElow cells were incubated in medium alone. Both populations were 
mixed in a 1:1 ratio and injected into immunized or control animals (i.v., 2.0 × 107 cells 
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total). After 18-h incubation, spleens were harvested, processed and analyzed by flow 
cytometry. Specific cytotoxicity was calculated based on a control ratio of recovery (RR) in 
naïve mice: (percentage of CFSElow cells)/(percentage of CFSEhigh cells). Percent specific 
lysis (%) = 100 × [1 – (RR of cells from naive mice/RR of cells from immunized mice) or 
100 × [1 – (RRnaive/RRimm)].
2.9. Determination of cytokine concentration in sera and culture supernatants
Free or SVP-encapsulated TLR agonists were serially diluted in tissue culture medium and 
added to J774 cells or fresh murine splenocytes. Culture supernatants were collected after 6–
48 h and assayed for TNF-α and IL-6 by ELISA (BD Biosciences, CA, USA). Local 
cytokine secretion was determined in culture supernatants after brief in vitro incubation of 
draining lymph nodes (LNs) from immunized animals. Briefly, popliteal LN were harvested 
at different intervals after injection of SVP, free TLR agonist, or PBS and were incubated 
individually (complete LN, without processing) for 16 h in 300 μl of supplemented 
RPMI-1640 with FBS as described above. Culture supernatants were then assayed for 
murine cytokines by ELISA using specific kits (BD Biosciences) or by multiplex ELISA 
biomarker assays (Aushon BioSystems, Billerica, MA, USA). Cytokine levels determined in 
the cultures from LNs of PBS-immunized animals were used as the initial time-point (0 h). 
Similarly, systemic cytokine levels in pooled or individual serum samples drawn from 
vaccinated animals via terminal bleeds at different time intervals after inoculation were 
measured by ELISA. Cytokine levels from the sera of PBS-immunized animals were 
considered as the initial time-point (0 h). All experiments on cytokine measurement in vivo 
were run two or three times yielding similar results for each experimental group.
2.10. Flow cytometry
At different time-points after injection with SVP, free TLR agonist or PBS, mice were 
sacrificed, draining popliteal lymph nodes harvested and digested for 30 min at 37 °C in 400 
U/mL collagenase type 4 (Worthington, Lakewood, NJ, USA). Single cell suspensions were 
prepared by forcing digested lymph nodes through a 70-μm nylon filter membrane, then 
washed in PBS containing 2% FBS and counted using a Countess® cell counter (Life 
Technologies, Carlsbad, CA, USA). Cells were stained pairwise with antibodies against the 
following mouse surface cell molecules: B220 and CD11c, CD3 and CD49b, F4/80 and Gr1 
(BD Biosciences, CA, USA). The gating logic was as follows: plasmacytoid dendritic cells 
(CD11c+, B220+), myeloid dendritic cells (CD11c+, B220−), B cells (CD11c−, B220+), 
granulocytes (GR-1+, F4/80−), macrophages (GR-1−, F4/80+), NK T cells (CD49b+, CD3+), 
NK cells (CD49b+, CD3−), and T cells (CD49b−, CD3+). Similarly, SIINFEKL-loaded 
pentamers (Proimmune, Oxford, UK), were used along with anti-mouse CD8 and CD19 (to 
gate out non-specific pentamer binding). Cell samples were then washed and immediately 
analyzed by flow cytometry. Data were analyzed with FlowJo software (Tree Star Inc., 
Ashland, OR, USA).
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3. Results
3.1. Nanoparticle encapsulation of TLR agonists changes the pattern of inflammatory 
cytokine induction in vitro
TLR7/8 (R848) and TLR9 (CpG ODN 1826; mouse-specific B-type CpG ODN) agonists 
were encapsulated in synthetic polymer nanoparticles and tested for their ability to induce 
cytokines in vitro. R848 was chemically conjugated to PLGA and used for SVP formulation 
as PLGA-R848, and CpG ODN was passively entrapped into SVP as described in Section 2. 
Natural oligonucleotide sequences contain a phosphodiester (PO) backbone, which is 
susceptible to rapid hydrolytic cleavage by nucleases in vivo. Nuclease-resistant CpG 
sequences with a phosphorothioate (PS) backbone have been shown to have superior activity 
to PO-CpG in vivo. Both PS and PO forms of the immunostimulatory CpG ODN 1826 
sequence (PS-CpG 1826 and PO-CpG 1826) were evaluated. SVP-encapsulated R848 
induced lower levels of TNF-α from splenocytes and especially from murine macrophages 
than identical amounts of free R848 (Fig. 1A and B). Similar profiles were seen when PS-
CpG 1826 and PO-CpG 1826 sequences were tested in free or SVP-encapsulated form. Not 
surprisingly, PO-CpG 1826 was a less potent inducer of TNF-α production than PS-CpG 
1826, with its SVP-encapsulated form being nearly inactive, even in the more sensitive J774 
cells (Fig. 1C and D). IL-6 production in vitro followed the same pattern as TNF-α (data not 
shown). However, a static in vitro system does not capture potential differences in 
biodistribution and pharmacokinetics of free adjuvant versus nanoparticle-encapsulated 
adjuvant that are expected in vivo.
3.2. Nanoparticle encapsulation of TLR7/8 agonist increases its adjuvant activity while 
antigen encapsulation increases immunogenicity in vivo
The adjuvant activity of nanoparticle-encapsulated R848 (SVP-R848) was assessed in vivo 
in immunogenicity studies with a model antigen, OVA (Fig. 2). The potency of free and 
SVP-encapsulated R848 to induce antibodies to OVA was compared in a standard prime-
boost immunization regimen. Both free and nanoparticle-encapsulated forms of OVA were 
tested (OVA and SVP-OVA, respectively). Additionally, R848 and OVA were either co-
encapsulated in the same particle (SVP-OVA-R848) or were admixed as separate particles 
(SVP-R848 and SVP-OVA). When admixed with soluble OVA, SVP-R848 resulted in nearly 
a 10-fold increase in immunogenicity compared to free R848 after two or three injections 
(Fig. 2). SVP-R848 exceeded the potency of alum, an adjuvant in numerous commercially 
approved vaccines, by an even higher margin (antibody titer EC50 values for animals 
immunized with OVA in alum were below the cut-off level for the assay). Notably, the 
presentation of OVA by SVP also resulted in a marked increase of antibody response (by at 
least 2–3 orders of magnitude) compared to free OVA with or without alum. Addition of free 
R848 to SVP-OVA further increased immunogenicity, especially after one or two injections, 
but its effect was not pronounced after the third vaccination. Free R848 was also inferior to 
encapsulated R848 whether it was co-encapsulated with OVA (SVP-OVA-R848) or present 
in a separate particle (SVP-OVA + SVP-R848). On average, co-encapsulation of OVA and 
R848 led to a 0.5-log increase in antibody titer compared to utilization of free R848, while 
admixing of SVP-OVA with SVP-R848 was more potent in antibody generation than 
addition of a free R848 to SVP-OVA by an order of magnitude (Fig. 2). While addition of 
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free R848 to SVP-OVA led to a clear Th1 shift in antibody response after two injections 
(IgG1:IgG2c ratios of 0.28 vs. 3.13 at day 40 for SVP-OVA + R848 and SVP-OVA, 
correspondingly), the difference was even more pronounced if R848 was SVP-encapsulated 
(IgG1:IgG2c ratios of 0.08 for SVP-OVA-R848 and 0.11 for SVP-OVA + SVP-R848).
Similarly, nanoparticle-encapsulated OVA and R848 induced strong local and systemic 
cellular immune responses (Fig. 3). Injection of nanoparticle-encapsulated R848 led to a 
significant influx of cells into draining lymph nodes (LN) even after a single inoculation 
(Fig. 3A). Moreover, utilization of encapsulated R848 (whether with free or co-encapsulated 
OVA) elevated both the percentage and absolute quantities of locally induced antigen-
specific CD8+ T cells, as assessed by reactivity with MHC class I pentamers containing the 
dominant ovalbumin epitope, SIINFEKL (Fig. 3B and C). Cells induced by co-encapsulated 
R848 and OVA exhibited a higher proliferative potential than when either free R848 or free 
OVA was utilized, as evidenced by in vitro expansion of OVA-specific CD8+ T cells (Fig. 
3D) and their cytotoxic activity (Fig. 3E). The in vivo cytotoxic activity was assessed at 6 
days after a single injection of nanoparticle-encapsulated or free OVA in the presence or 
absence of free or nanoparticle-encapsulated R848. SIINFEKL-pulsed syngeneic target cells 
were eliminated efficiently in vivo only if both OVA and R848 were delivered in 
encapsulated form (Fig. 3F). The level of in vivo cytotoxic activity was maintained for 
several days after a single injection (data not shown). The admix of nanoparticle-
encapsulated OVA with free R848 or the admix of free OVA with nanoparticle-encapsulated 
R848 induced poor in vivo cytotoxic activity (Fig. 3F).
3.3. Rapid infiltration of draining lymph nodes by innate and adaptive immune cells upon 
injection of nanoparticle-encapsulated R848
R848-bearing nanoparticles induced a profound increase in cellularity within the draining 
lymph nodes at 4 days after a single inoculation (Fig. 3A). Further analysis of cellularity 
within the draining lymph nodes after s.c. injection showed that LN infiltration starts as 
early as 1 day after inoculation, reaches a peak at 7–8 days, and is maintained for at least 3 
weeks (Tables 1 and 2). The increase in lymph node cellularity was even more rapid and 
pronounced in mice that were previously immunized with SVP (10-fold increase in the 
popliteal LN cell count at 1 day after inoculation, Table 2). No significant cell infiltration of 
the draining lymph node was seen if SVP lacking R848 were used either alone or admixed 
with free R848 (Table 1).
A detailed analysis of intranodal cell populations after SVP-R848 injection showed a rapid 
increase in the number of innate immune cells, such as granulocytes and myeloid DC, in the 
draining LN, with their numbers increasing 3-fold within 24 h after a single injection (Table 
3). There was also an early elevation in macrophage cell numbers in the draining lymph 
node, while increases in other APC subtypes (plasmacytoid DC and B cells) were observed 
at a slightly later time-point. Interestingly, among the populations analyzed, only effector 
cells of the adaptive immune response (T and B cells) showed a continued expansion from 
day 4 to day 7 (Table 3).
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3.4. Nanoparticle encapsulation of TLR7/8 agonist induces strong local cytokine 
production
Strong local immune activation by nanoparticle-encapsulated R848 was further manifested 
by cytokine production in the draining LN milieu (Figs. 4 and 5). At 4 h after subcutaneous 
injection, high levels of IFN-γ, RANTES, IL-12(p40) and IL-1β were secreted by LNs from 
animals injected with SVP-OVA-R848, while the production of these cytokines by LNs from 
mice injected with free R848 was close to the background level (Fig. 4). In particular, the 
amount of IFN-γ secreted by LNs from mice injected with SVP-OVA-R848 at 4 h was more 
than 100-fold higher than that from the LNs of mice injected with SVP-OVA and an equal 
amount of free R848 (Fig. 4A), while RANTES was elevated more than 27-fold (Fig. 4B). 
Production of all of these cytokines in the LN was maintained for at least 72 h after injection 
of SVP-OVA-R848, with levels of IL-12(p40) and IL-1β remaining nearly stable (Fig. 4C 
and D), and levels of IFN-γ and RANTES, while decreasing, remaining 4- to 20-fold higher 
than the background. In contrast, inoculation of free R848 led to only a modest increase of 
local cytokine production at 4 h, which returned to background levels by 24 h after 
administration. Levels of IP-10 and MCP-1 in LNs from SVP-OVA-R848-injected animals 
were also elevated in a similar fashion (data not shown).
The striking difference in local cytokine production after administration of nanoparticle-
encapsulated versus free R848 (Fig. 4) was also evident by comparing cytokine production 
in the ipsilateral draining lymph node versus the contralateral lymph node after injection in a 
single hind limb (Fig. 5A and B). The sustained expression of IFN-γ, IL-12(p40), and IL-1β 
was seen in the ipsilateral LN at 4–48 h after injection of SVP-R848, but not in the 
contralateral lymph node. In contrast, free R848 induced a modest elevation of IL-12(p40) 
and IFN-γ in both the ipsilateral and contralateral lymph nodes (Fig. 5B). The level of IFN-γ 
observed in the ipsilateral lymph node following injection of free R848 was 50-fold lower 
than that induced by SVP-R848 (Fig. 5A). No induction of IL-1β by free R848 was seen 
(Fig. 5C).
3.5. Nanoparticle encapsulation of TLR7/8 agonist R848 attenuates the production of 
systemic inflammatory cytokines
While nanoparticle encapsulation of R848 enhanced immunogenicity and local induction of 
immune cytokines, the production of systemic inflammatory cytokines by SVP-R848 was 
markedly suppressed compared to that observed with free R848 after either subcutaneous or 
intranasal inoculation (Figs. 6 and 7, respectively). In particular, 4 h after subcutaneous 
inoculation, serum concentrations of early inflammatory cytokines TNF-α and IL-6 were 
50–200 times higher if free R848 was used (Fig. 6A and B). Serum cytokine levels were 
similar in animals inoculated with SVP-OVA with or without encapsulated R848. Similar 
differences were observed with systemic production of RANTES (Fig. 6C). SVP-OVA-R848 
induced modest levels of IP-10, IL-12(p40), and MCP-1, which were approximately 5–10 
times lower than that observed after injection of SVP-OVA admixed with free R848 (Fig. 
6D–F).
Patterns of systemic cytokine expression profiles after intranasal delivery of either free or 
encapsulated R848 (Fig. 7) were similar to those seen after s.c. delivery. Serum TNF-α and 
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MCP-1 were only weakly induced by SVP-R848, with levels 10- to 100-fold lower than 
those induced by free R848 (Fig. 7A and D), while levels of IL-6 and IL-12(p40) induction 
were 5 times lower (Fig. 7B and C).
3.6. Nanoparticle encapsulation of TLR9 agonist permits effective utilization of 
immunostimulatory phosphodiester CpG ODNs in vivo
We next assessed the adjuvant activity of a nanoparticle-encapsulated TLR9 agonist, 
CpG-1826, in immunogenicity studies with a model antigen, OVA. It is known that a PO 
form of CpG is subject to rapid degradation by nucleases [36,46] and therefore the 
backbone-modified PS form is usually employed in vivo. We reasoned that nanoparticle 
encapsulation may protect the PO form from premature degradation and enable use of PO-
CpG in vivo. Co-administration of nanoparticle-encapsulated OVA and PO-CpG 1826 
induced antibody titers comparable to that obtained with nanoparticle-encapsulated OVA 
admixed with the same dose of free PS-CpG 1826 (Fig. 8A). Animals immunized with the 
same doses of free OVA admixed with free PS-CpG 1826 exhibited 20- to 40-fold lower 
antibody titers (Fig. 8A). Increasing the dose of free OVA and free PS-CpG 1826 did not 
increase the antibody titers compared to SVP-encapsulated OVA and PO-CpG (Fig. 8B). 
When another antigen, prostatic acid phosphatase (PAP), was evaluated, PS-CpG 1826 was 
inferior by nearly two orders of magnitude in antibody induction compared to nanoparticle-
encapsulated PAP and PO-CpG 1826 (Fig. 8C). Nanoparticle entrapment of PS-CpG 1826 
did not lead to higher immunogenicity compared to entrapped PO-CpG 1826, while 
utilization of free PO-CpG 1826 resulted in no augmentation of immunogenicity (data not 
shown). When nanoparticle-encapsulated OVA and PO-CpG 1826 were compared to free 
OVA and free PS-CpG 1826 in their ability to induce specific CTLs in vivo, the combination 
of the former was more effective even if 10 times more free OVA and 5 times more free PS-
CpG 1826 were used (Fig. 9).
No significant induction of inflammatory cytokines (TNF-α, IL-6) in serum was seen when 
free or encapsulated PO and PS forms of CpG-1826 were tested, while free PS-CpG 1826 
induced the production of IL-12(p40) to the same levels as nanoparticle-encapsulated PO-
CpG 1826 (Table 4). Nanoparticle entrapment of PS-CpG 1826 led to elevated and sustained 
local production of IFN-γ, IL-12(p40), and IL-1β, which exceeded that of free PS-CpG 1826 
(used in 10-fold excess, Fig. 10), closely paralleling results seen when free and SVP-
encapsulated R848 were compared (Fig. 7). No cytokine induction from contralateral LN 
was observed after SVP-PS-CpG inoculation (Fig. 10).
4. Discussion
TLR7/8 and TLR9 agonists have shown great promise as immunomodulating therapeutic 
agents [52–61; reviewed in 36] and as adjuvants for DNA- [62] and protein-based vaccines 
[63–67]. Both R848 and CpG ODNs were seen as attractive candidates for systemic use in a 
variety of settings [see summaries in 12,31,36,40,68] due to TLR7/8 and TLR9 distribution 
in immune cells and resulting ability of these compounds to specifically activate APCs (i.e., 
dendritic cell, monocyte/macrophage, and B cell populations). However, broad use of 
TLR7/8 and 9 agonists as parenteral drugs and adjuvants has been limited due to systemic 
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toxicity [13,69], which is directly related to systemic cytokine release [70]. We hypothesized 
that encapsulation of a TLR agonist into a nanoparticle carrier may attenuate systemic 
cytokine induction and thus enable its use as a parenterally administered adjuvant. 
Nanoparticle delivery of TLR7/8 or TLR9 agonists would have multiple benefits, including 
(1) minimizing systemic exposure of the TLR agonist, (2) delivering of adjuvant to lymph 
nodes via direct flow of nanoparticles through draining lymphatics [43,44], (3) promoting 
uptake into endosomal vesicles of APC, where TLR7, 8, and 9 are expressed, and (4) 
providing a sustained release of the TLR agonist from a nanocarrier rather than a bolus 
delivery. Moreover, nanoparticle encapsulation of both antigen and adjuvant may have a 
synergistic benefit by enabling co-delivery of both antigen and adjuvant to APCs as 
demonstrated earlier for microparticle delivery vehicles [40,46].
R848 is a highly potent TLR7/8 agonist that rapidly distributes throughout the body and 
exhibits a short half-life [12]. While imiquimod, an analog of R848 which is 100-fold less 
potent, is licensed as a topical drug for genital warts, actinic keratosis, and basal cell 
carcinoma [31], clinical development of R848 as a topical drug and as an orally-delivered 
drug was discontinued due to its narrow therapeutic window related to its short in vivo half-
life and systemic side-effects. Our results demonstrate that encapsulating R848 may greatly 
increase its therapeutic window. Free R848 administered s.c. induced serum TNF-α and IL-6 
levels that were 50- to 200-fold higher than that observed with SVP-encapsulated R848. The 
systemic production of TNF-α, IL-6, and RANTES was suppressed in SVP-R848-injected 
animals to background levels, while systemic induction of IP-10 and MCP-1 was also 
greatly attenuated. The reduction in systemic cytokine production is likely due to delivery of 
nanoparticles to the local draining lymph, direct uptake by APCs, and sustained release of 
R848 over time. Consistent with this hypothesis, we observed a strong and sustained local 
immune activation following subcutaneous administration of SVP-R848, as evidenced by 
cellular infiltration of the draining LN by APC followed by effector cells, leading to 
prolonged local production of IFN-γ, IL-12(p40) and IL-1β. In contrast, only low levels of 
LN cellular infiltration and local cytokine production were seen upon administration of free 
TLR7/8 agonist. Notably, SVP encapsulation of R848 led to a strong induction of cellular 
immune responses (both local and systemic) even after a single immunization, while free 
R848 was nearly inactive.
Our results confirm and advance the recent findings of Tacken et al. who reported that 
nanoparticle encapsulation of TLR3 and 7/8 agonists attenuated the serum cytokine storm 
and enhanced immunogenicity [71]. In this case, R848 was passively entrapped within the 
nanoparticle and required antibody-mediated DC targeting for delivery. The reduction in 
cytokine storm (measured at a single time-point) was not as pronounced as observed in the 
present study with the SVP-based platform, even though we used 20-fold more R848 [71]. 
This difference may be due to our use of SVP that contained R848 covalently linked to the 
PLGA polymer with an acid-labile bond, a design intended to constrain R848 release to the 
acidic environment within the endosome.
SVP encapsulation of a TLR9 agonist, CpG-1826, also provided significant benefit. 
CpG-1826 belongs to type B CpG, capable of activating B cells and inducing the production 
of proinflammatory cytokines [14,72,73]. CpG-1826 encapsulation within SVP provided for 
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higher local cytokine production and, when co-delivered with encapsulated antigen, resulted 
in higher immune responses than antigen admixed with free CpG-1826. Unmodified CpG 
contains a nuclease-labile phophodiester backbone (PO-CpG) which is known to be rapidly 
degraded in vivo, thus parenterally administered free CpG must be modified to contain a 
nuclease resistant phosphorothioate backbone (PS-CpG) to be active in vivo. Importantly, 
SVP encapsulation enabled utilization of the non-phosphorothioate form of CpG (i.e., PO-
CpG) with the same efficiency as PS-CpG. The use of PO-CpG in SVPs may further reduce 
the potential for systemic immune activation, as any PO-CpG that leaks out of the 
nanoparticles will be rapidly degraded.
Nanoparticle encapsulation of both antigen and adjuvant may have a synergistic benefit by 
enabling co-delivery of both antigen and adjuvant to APC. The SVP technology allows for 
either covalent or non-covalent entrapment of a TLR agonist as well as covalent and non-
covalent presentation of antigen on the surface or within the nanoparticle. The SVPs are 
designed to release their payload in the low pH environment of the endolysosomal 
compartment of APC, which contains TLR7, 8, and 9 as well as MHC class II molecules. 
The sustained and concomitant release of antigen and adjuvant from SVPs could also 
contribute to more potent immune responses and better memory cell generation. Our data 
show that adjuvant and antigen can be delivered in separate nanoparticles. The ability to 
utilize independently formulated antigen- and TLR-agonist-carrying nanoparticles may be 
advantageous for modular and flexible vaccine design. For example, a two particle approach 
can provide flexibility in dosing to optimize the ratio of adjuvant-to-antigen for a particular 
application.
While vaccines have been an effective and cost-efficient health care intervention for the 
prophylaxis of many infectious pathogens, new vaccine technology and more potent 
adjuvants may be required to develop effective therapeutic vaccines for chronic infections, 
intracellular pathogens, and non-infectious diseases, such as cancer. The immune system is 
keyed to respond to particulate antigens, such as viruses and bacteria. Synthetic 
nanoparticles can mimic key elements of viral particles by co-delivering antigen with strong 
TLR agonists and effectively induce robust cellular and humoral immunity. Finally, one can 
envision that other immunomodulatory agents could be incorporated into SVPs to further 
fine-tune the immune response by targeting specific subsets of immune cells, such as CD8 T 
cells, Th1 cells, Th2 cells, Tfh, Th17 cells, T regulatory cells, B cells, and NK T cells.
Collectively, the data reported here suggest an approach to utilize TLR agonists as 
parenterally administered vaccine adjuvants in a clinical setting while minimizing the risk of 
systemic adverse reactions. Co-encapsulation of antigen has the added benefit of co-delivery 
of adjuvant and antigen directly to APCs. The SVP approach is currently being evaluated in 
pre-clinical studies such as cancer and chronic infections, where traditional adjuvants are 
inadequate, and in a Phase 1 clinical study for smoking cessation, where high concentrations 
of antibodies against nicotine are thought to be necessary for therapeutic efficacy.
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DC dendritic cell
LN lymph node
ODN oligonucleotide
PAMP pathogen-associated molecular pattern
PAP prostatic acid phosphatase
PO phosphodiester
PS phosphorothioate
PRR pattern recognition receptor
SVP synthetic vaccine particle
Tfh follicular helper T cells
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Fig. 1. 
Adjuvant encapsulation in nanoparticles (SVP) results in suppressed TNFα induction in 
murine cells in vitro. SVP containing TLR7/8 agonist R848 (A, B) or TLR9 agonists PO-
CpG 1826 (C) or PS-CpG1826 (D) were added to J774 cells (A, C) or fresh mouse 
splenocyte cultures (B, D) in parallel with free adjuvants in triplicates. The amount of TNF-
α in culture supernatants was measured 6 h (splenocytes) or 16 h (J774) after incubation. 
Representative results out of two separate experiments with groups of three mice are shown.
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Fig. 2. 
Nanoparticle encapsulation of both antigen and TLR7/8 agonist (R848), whether co-
encapsulated or in separate particles, results in a higher humoral immune response than 
utilization of free TLR7/8 agonist and/or free antigen. Groups of 5–10 mice were 
immunized (3 times, 4-week intervals, s.c., hind limb) with various combinations of SVP-
OVA or free OVA and/or SVP-R848 or free R848, as indicated. The same dose of OVA (5.6 
μg) was used in all experimental groups and the same dose of R848 (6.8 μg) was used in all 
groups in which R848 was administered. Antibody generation was measured by ELISA at 
the indicated time-points and is presented as log10 of EC50 with standard deviations.
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Fig. 3. 
Nanoparticle encapsulation of both antigen and TLR7/8 agonist (adjuvant) results in higher 
local and systemic cellular immune responses than utilization of free antigen or adjuvant. A 
– total draining lymph node (LN) cell count, B – SIINFEKL-positive CD8+ T cells in 
draining lymph node (absolute numbers – gray bars, left Y-axis; percentage of total CD8+ T 
cells – hatched bars, right Y-axis), C – flow cytometric analysis of SIINFEKL-positive CD8+ 
T cells ex vivo, D – flow cytometric analysis of SIINFEKL-positive CD8+ T cells after in 
vitro expansion, E – in vitro cytotoxic activity of LN-derived cells against OVA-expressing 
target cells, and F – in vivo cytotoxicity against SIINFEKL-pulsed syngeneic splenocytes. 
Groups of 3–6 mice were injected (s.c., hind limb) either with SVP-encapsulated or free 
OVA and/or R848 in combinations indicated. At 4 days after injection, total cells in the 
popliteal LNs were isolated and counted (A). LN cells were then stained for surface markers 
either immediately (B, C) or after 4 days of in vitro expansion on IL-2 without feeder/
stimulator cells (D). The percentage of antigen-specific CTL stained with SIINFEKL-MHC 
class I pentamer and anti-CD8 antibody was assessed by flow cytometry (indicated in boxes 
in C and D; samples from two representative animals shown). In vitro cytotoxic activity was 
assessed after in vitro expansion of LN cells, as described. The difference between specific 
(E.G7-OVA transfected targets cells) and non-specific (EL-4 parental cells) cytotoxicity is 
shown (E). The amount of free or SVP-encapsulated OVA and R848 in μg/injection dose is 
indicated in parentheses. The effector-to-target ratio (E:T ratio) is depicted in the x-axis. In 
vivo CTL activity (F) was assessed in mice (n = 2–4/group) injected s.c. with SVP-
encapsulated or free OVA either alone or with free or SVP-encapsulated R848, as indicated. 
The total dose of OVA was the same across all treatment groups, and the total dose of R848 
was the same for all groups receiving R848. Specific in vivo cytotoxicity was determined as 
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described in Section 2 at 6 days post-immunization. All experiments presented in this figure 
were run 2–3 times.
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Fig. 4. 
Local cytokines are induced by SVP-encapsulated, but not free, TLR7/8 agonist R848. Mice 
were injected s.c. in both hind limbs with either SVP-OVA-R848, SVP-OVA, or SVP-OVA 
admixed with free R848. At the times indicated, popliteal LNs were taken and incubated in 
vitro overnight. Culture supernatants were collected and analyzed for the presence of 
specific cytokines by ELISA. A – IFN-γ, B – RANTES, C – IL-12(p40), D – IL-1β. Average 
of four LNs per time-point is shown.
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Fig. 5. 
Focused local cytokine induction after a single-site injection with SVP-encapsulated, but not 
free, TLR7/8 agonist R848. Mice were injected s.c. in a single hind limb with either SVP-
R848 or free R848. At the times indicated, popliteal LNs from the injection side (ipsilateral, 
I) and from the opposite side (contralateral, C) were collected and incubated in vitro 
overnight. Culture supernatants were analyzed for the presence of specific cytokines by 
ELISA. A – IFN-γ, B – IL-12(p40), C – IL-1β. Average of two mice per time-point is 
shown.
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Fig. 6. 
Strong systemic cytokine induction after injection of free, but not SVP-encapsulated TLR7/8 
agonist R848. Mice were injected s.c. with either SVP-OVA-R848, SVP-OVA or SVP-OVA 
admixed with free R848 and bled at times indicated. The same amount of free or SVP-
encapsulated R848 was used for each group (6.8 μg). Serum samples were collected at the 
times indicated and analyzed for individual cytokines by ELISA. Average cytokine 
concentration is shown (three samples per group per each time-point). A – TNF-α, B – IL-6, 
C – RANTES, D – IP-10, E – IL-12(p40), F – MCP-1.
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Fig. 7. 
Systemic cytokine induction after intranasal inoculation of free, but not SVP-encapsulated 
TLR7/8 agonist R848. Mice were inoculated intranasally with either SVPOVA-R848, SVP-
OVA, or SVP-OVA admixed with free R848 and bled at times indicated. The same amount 
of free or SVP-encapsulated R848 was used for each group (3.8 μg). Serum samples were 
collected at the times indicated and analyzed for individual cytokines by ELISA. Average 
cytokine concentration is shown (three samples per group per each time-point). A – TNF-α, 
B – IL-6, C – IL-12(p40), D – MCP-1.
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Fig. 8. 
Higher humoral immunogenicity of SVP-encapsulated antigen coupled with free TLR9 
agonist PS-CpG or with SVP-encapsulated TLR9 agonist PO-CpG. Mice (5/group) were 
immunized (s.c., hind limb) with the indicated SVP or combinations of free antigen and PS-
CpG 1826. Antibody titers were determined at times indicated. Mice were immunized either 
two (A, C) or three (B) times with 2-week intervals between immunizations. OVA (A, B) 
and prostatic acid phosphatase (PAP) (C) proteins were evaluated as test antigens, either in 
free form or encapsulated in SVP. In Panel B, the total dose of both free OVA and free PS-
CpG 1826 was five times greater than that administered in the SVP-treated groups. In Panel 
C, the amount of free PAP used was 50 times higher than that of SVP-encapsulated PAP, and 
the amount of free PS-1826 was two times higher than used in SVP-encapsulated form (C). 
No adjuvant effect of free PO-1826 was detected (data not shown).
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Fig. 9. 
Nanoparticle encapsulation of both antigen and TLR9 agonist PO-CpG (adjuvant) results in 
a higher local cellular immune response than utilization of free antigen and adjuvant. Groups 
of 2–3 mice were injected (s.c., hind limb, once or twice with 2-wk interval) with a 
combination of SVP-encapsulated OVA and SVP-encapsulated PO-CpG 1826, free OVA 
admixed with free PS-CpG 1826, or PBS as indicated. The amount of free OVA (50 μg) was 
ten times higher and the amount of free PS-CpG 1826 (20 μg) was five times higher than 
that present within SVP (5 and 4 μg, respectively). Tissues were taken at 5 days after the last 
immunization and restimulated in vitro for 7 days with mitomycin-treated E.G7-OVA cells. 
LN cells were stained with surface marker antibodies and analyzed by flow cytometry. Top 
row – popliteal LN cultures (initiated 5 days after a single immunization), bottom row – 
splenocyte cultures (initiated 5 days after prime-boost immunization). Representative flow 
cytometry dot plots from two separate experiments are shown. The numbers indicate the 
percentage of CD8+ T cells that are specific for the OVA SIINFEKL peptide (percent share 
of CD8+CD19− cells).
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Fig. 10. 
Focused local cytokine induction by SVP-encapsulated, but not free TLR9 agonist CpG. 
Mice were injected s.c. in a single hind limb with either SVP-PS-CpG 1826 or free PS-CpG 
1826. At the times indicated, popliteal LNs from the injection side (ipsilateral, I) and from 
the opposite side (contralateral, C) were taken and incubated in vitro overnight. Culture 
supernatants were collected and analyzed for cytokine presence by ELISA. A – IFN-γ, B – 
IL-12(p40), C – IL-1β. Average of two mice per group per time-point is shown.
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Table 1
Local lymphadenopathy induction by administration of SVP-encapsulated but not free TLR7/8 agonist.
Day SVP-R848 SVP (no adjuvant) SVP (no adjuvant) + R848
0 1.00 1.00 1.00
1 1.50 1.36 1.08
4 3.19 1.53 1.03
7 8.06 1.53 0.84
Mice were injected subcutaneously (hind limb) with SVP-R848, SVP (no adjuvant) or SVP (no adjuvant) admixed with free R848. Popliteal LNs 
were taken at various times as indicated. Total lymph node cells (normalized to day 0 values) in all groups (average of 3 mice per time-point) are 
shown.
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Table 2
Local lymphadenopathy after administration of SVP-encapsulated TLR7/8 agonist and antigen in naïve vs. 
pre-immunized mice.
Day SVP-R848, total cells in LN
Naïve mice Immune mice
0 1.00 1.00
3 4.33 10.14
8 8.04 9.86
14 5.36 6.93
21 4.14 6.60
Naive or previously immunized mice were injected with SVP-R848 with co-encapsulated antigen (hind limb, s.c.). Popliteal LNs were taken at 
various times as indicated. Total lymph node cell counts (normalized to day 0 values) in all groups (average of 3 mice per time-point) are shown.
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Table 3
Local lymphadenopathy and immune cell population expansion after administration of SVP-encapsulated 
TLR7/8 agonist.
Day Total cells CD11c
+
 B220−
(mDC)
CD11c+ B220+
(pDC)
B220+ CD11c−
(B cells)
F4/80+ GR1−
(Mø)
F4/80− GR1+
(Gran) CD3
+
 (T cells) CD3
−
 CD49b+
(NK)
CD3+ CD49b+
(NKT)
0 1.00 1.00 1.00 1.00 1.000 1.00 1.00 1.00 1.00
1 1.50 3.15 1.36 0.98 1.97 3.52 1.52 1.03 0.62
4 3.19 6.50 8.14 3.56 1.16 14.20 2.54 9.64 6.72
7 8.06 7.00 7.77 11.09 2.51 18.43 4.39 8.57 8.25
Mice were injected s.c. (hind limb) with SVP-R848, SVP (no adjuvant), or SVP (no adjuvant) admixed with free R848. Popliteal LNs were taken at 
times indicated. Total lymph node cells were counted, stained for various surface markers, as indicated, and analyzed by flow cytometry. Cell 
numbers were normalized to day 0 values. Data shown in table are from SVP-R848 injected mice. No marked variation in LN cell populations was 
seen in mice injected with “no adjuvant”-SVP or “no adjuvant”-SVP admixed with free R848 (not shown). Mø – macrophages, mDC and pDC – 
myeloid and plasmacytoid DC, Gran – granulocytes, NKT – NK T cells.
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Table 4
Systemic cytokine induction after subcutaneous administration of SVP-encapsulated or free TLR9 agonist.
Cytokine peak concentration (pg/mL)
Mice injected with TNF-α IL-6 IL-12(p40)
SVP-OVA 1.4 67.2 43.9
SVP-OVA + SVP-PO-CpG 1826 11.2 105.2 569.4
SVP-OVA + PO-CpG 1826 2.2 79.6 44.0
SVP-OVA + PS-CpG 1826 12.8 58.7 448.0
Mice were injected subcutaneously (hind limb) with either SVP-OVA alone or combined with SVP-PO-CpG 1826, free PO-CpG 1826, or free PS-
CpG 1826 and bled at 0.5, 1, 1.5, and 3 h after injection. Peak average cytokine concentration in serum is shown (three samples per group for each 
time-point).
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